Proposed study to examine CV event risk associated with GLP-1RAs and SGLT-2i, to determine if these therapies reduce the incidence of heart disease in women with type 2 diabetes. It appears that this request is not for IPD, but simply for the absolute rates from the CANVAS trial. Might the CSR be sufficient? This estimate will then be aggregated with others ascertained from the medical literature.
Recommendation for this data request: Approve